Trial Profile

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perampanel (Primary)
Indications Epilepsy
Focus Adverse reactions
Sponsors Eisai Co Ltd

Most Recent Events

28 Apr 2017 Results assessing long term efficacy and safety presented at the 69th Annual Meeting of the American Academy of Neurology.
06 Dec 2016 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 70th Annual Meeting of the American Epilepsy Society.
06 Dec 2016 Results presented at the 70th Annual Meeting of the American Epilepsy Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com